Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 15/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 2/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27077832 | 0.86 | NPBWR1 (0.51) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL29731573 | 0.84 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL29102671 | 0.84 | NPBWR1 (0.68) | NPBWR1MCHR1PKMALDH1A1HTT | |
| SCHEMBL29731534 | 0.84 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL24640501 | 0.84 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL27077877 | 0.83 | NPBWR1 (0.66) | NPBWR1MCHR1PKMALDH1A1HTT | |
| SCHEMBL29150302 | 0.81 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL27435441 | 0.80 | NPBWR1 (0.53) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL27077749 | 0.80 | NPBWR1 (0.55) | NPBWR1MCHR1PKMPKLRPDE1A | |
| SCHEMBL27077660 | 0.79 | NPBWR1 (0.57) | NPBWR1MCHR1PKMPKLRPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | NPBWR1 830/4885MCHR1 1306/4885PKM 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.